compounded semaglutide ban update & Tirzepatide 2025: Safe Use Guide Compounded "semaglutide" is not FDA-approved

Side-effect management: Nausea and GI issues are minimal at lower doses

You assume all responsibility for legal compliance, proper handling, and storage

Depending on your situation, useful documentation may include: Current height, weight, and BMI Baseline weight and BMI before GLP-1 therapy, if you previously used medication Weight-related diagnoses such as obesity, hypertension, sleep apnea, diabetes, cardiovascular disease, or fatty liver disease Medication history and prior treatment attempts Recent labs, imaging, sleep study reports, cardiology notes, or liver-related records when relevant Prior authorization denial letters or pharmacy rejection messages Current Medicare Part D or Medicare Advantage drug plan information What to Bring to Your Medicare GLP-1 Visit To make your consultation more productive, please bring: Your Medicare card Your Part D or Medicare Advantage drug plan information Your current medication list, including supplements Recent lab results, if available Prior denial letters, pharmacy messages, or prior authorization notices Records related to cardiovascular disease, sleep apnea, diabetes, hypertension, obesity, fatty liver disease, or other weight-related diagnoses Your current pharmacy information What to Expect at Your Medicare GLP-1 Visit During a consultation at our Sterling Heights or Bingham Farms office, we typically: Review your medical history Complete a weight and BMI evaluation Review labs or order new labs if needed Discuss medication options and whether GLP-1 therapy is appropriate Review safety, side effects, contraindications, and medication interactions Discuss coverage pathways and documentation needs Build a personalized treatment plan tailored to your health goals Medication decisions are made after a complete medical evaluation

This translated into seven fewer new substance use disorder diagnoses per 1,000 GLP-1 users

PlexusDx offers GLP-Squared Injection (compounded semaglutide + tirzepatide dual-agonist) starting at $249 per month, which activates both GLP-1 and GIP receptor pathways without cardiovascular risk

Putting guidelines into practice Will these guidelines change how your doctor checks and treats your cholesterol